ANDA 200250, held by Glenmark Pharms Ltd. Levofloxacin.
As of Nov 16, 2026, ANDA 200250 (Levofloxacin), held by Glenmark Pharms Ltd, was first approved by FDA on Jun 20, 2011, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 20, 2011 | Original application | Approved | None posted |
| Levofloxacin250MG · tablet;oral | Levofloxacin | Rx |
| Levofloxacin500MG · tablet;oral | Levofloxacin | Rx |
| Levofloxacin750MG · tablet;oral | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 10, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 10, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 29, 2012 | Supplement 2Labeling | Approved | None posted |
| Aug 2, 2011 | Supplement 1Labeling | Approved | None posted |
| Jun 20, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters